Shares of Novavax, Inc. (NVAX) traded 16% higher on Thursday morning after the company reported upbeat first-quarter (Q1) ...

Novavax said on Thursday discussions with the U.S. health regulator on its COVID-19 shot are ongoing and a pathway to ...

Novavax (NVAX) delivered earnings and revenue surprises of 312.68% and 215.04%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Novavax (NVAX) stock jumps 35% as the company raises its 2025 revenue outlook and its Q1 2025 financials surpasses forecasts ...

The average estimate of five analysts surveyed by Zacks Investment Research was for earnings of 71 cents per share. The vaccine maker posted revenue of $666.7 million in the period, also beating ...

NVAX: Retail traders are celebrating Novavax's massive first-quarter earnings beat that was released before Thursday's ...

Analysts are estimating that Novavax will report an earnings per share (EPS) of $0.19. The market awaits Novavax's ...

Novavax, Inc. (NVAX) said it has updated the terms of the collaboration and licensing agreement with Takeda. The company noted that the improved financial terms of the amended ...

Novavax Inc. closed 73.72% short of its 52-week high of $23.86, which the company achieved on June 6th.

Improved financial terms for Novavax and streamlined operations will help both companies better meet the needs of the Japanese market Nuvaxovid®, a protein-based ...

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in ...

In the most recent trading session, Novavax (NVAX) closed at $6.41, indicating no shift from the previous trading day.